Adverse effect · CJC-1295

How common is safety in humans with CJC-1295?

C
Grade C — weak human evidenceEarly-phase only · effect size: not measurable · adverse
Short answerWeak human evidence. Early-phase only: enough to be interesting, not enough to count on. Where an effect is seen it is no measurable effect, or none yet shown. Short early-phase exposure only. Long-term safety of sustained IGF-1 elevation is unstudied.

What the studies show

Short early-phase exposure only. Long-term safety of sustained IGF-1 elevation is unstudied.

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

In context

CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.

CJC-1295 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is CJC-1295 proven to cause safety in humans?
No. The human evidence is weak (Early-phase only); LYO grades it C.
What studies are behind the grade?
Short early-phase exposure only. Long-term safety of sustained IGF-1 elevation is unstudied.
Is CJC-1295 approved for this?
No. CJC-1295 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for CJC-1295

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →